No connection

Search Results

Corporate Score 42 Bearish

Spruce Biosciences Launches $60 Million Offering to Advance Neuro-Therapies

Apr 21, 2026 08:58 UTC
SPRB
Immediate term

Spruce Biosciences is raising $60 million through a public offering of common shares and warrants. The capital is earmarked for the development of therapies targeting neurological disorders.

  • Offering priced at $50.00 per share
  • Total gross proceeds expected to reach $60 million
  • Capital dedicated to neurological disorder research
  • Offering scheduled to close on April 22
  • Overnight share price decline of 12.15%

Spruce Biosciences Inc. (SPRB) has announced the pricing of a public offering intended to generate $60 million in gross proceeds. The funds are designated to accelerate the company's research and development efforts within its neurological disorder therapy pipeline. The offering involves the sale of 1.15 million common shares priced at $50.00 per share. This move comes as the late-stage biopharmaceutical firm seeks to bolster its balance sheet to support clinical advancements and operational growth. In addition to the common shares, certain investors will receive pre-funded warrants to purchase 50,000 shares at a price of $49.99, which represents the offer price minus a $0.01 exercise fee. The transaction is expected to close on April 22, with underwriters holding a 30-day option to acquire up to 180,000 additional shares. The market reacted negatively to the news of dilution, with SPRB shares falling 12.15% in overnight trading to $61.40. This follows a Monday close of $69.90, reflecting investor concerns over the immediate impact of the share issuance on equity value.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile